Literature DB >> 20652564

Interim PET in lymphoma: a step towards standardization.

Michel Meignan.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20652564     DOI： 10.1007/s00259-010-1546-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  14 in total

1.  Hematology. Are macrophages the bad guys in Hodgkin lymphoma?

Authors:  Volker Diehl
Journal:  Nat Rev Clin Oncol       Date:  2010-06       Impact factor: 66.675

2.  Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background.

Authors:  Emmanuel Itti; Malik E Juweid; Corinne Haioun; Imene Yeddes; Fatma Hamza-Maaloul; Intidhar El Bez; Eva Evangelista; Chieh Lin; Jehan Dupuis; Michel Meignan
Journal:  J Nucl Med       Date:  2010-11-15       Impact factor: 10.057

3.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

Authors:  Sally F Barrington; Wendi Qian; Edward J Somer; Antonella Franceschetto; Bruno Bagni; Eva Brun; Helén Almquist; Annika Loft; Liselotte Højgaard; Massimo Federico; Andrea Gallamini; Paul Smith; Peter Johnson; John Radford; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-27       Impact factor: 9.236

4.  Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.

Authors:  Chieh Lin; Emmanuel Itti; Corinne Haioun; Yolande Petegnief; Alain Luciani; Jehan Dupuis; Gaetano Paone; Jean-Noël Talbot; Alain Rahmouni; Michel Meignan
Journal:  J Nucl Med       Date:  2007-09-14       Impact factor: 10.057

5.  Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.

Authors:  Emmanuel Itti; Chieh Lin; Jehan Dupuis; Gaetano Paone; Daniela Capacchione; Alain Rahmouni; Corinne Haioun; Michel Meignan
Journal:  J Nucl Med       Date:  2009-03-16       Impact factor: 10.057

6.  Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation.

Authors:  Andrea Gallamini; Francesca Fiore; Roberto Sorasio; Michel Meignan
Journal:  Leuk Lymphoma       Date:  2009-11

7.  Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

Authors:  Craig H Moskowitz; Heiko Schöder; Julie Teruya-Feldstein; Camelia Sima; Alexia Iasonos; Carol S Portlock; David Straus; Ariela Noy; Maria L Palomba; Owen A O'Connor; Steven Horwitz; Sarah A Weaver; Jessica L Meikle; Daniel A Filippa; James F Caravelli; Paul A Hamlin; Andrew D Zelenetz
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

8.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Authors:  Andrea Gallamini; Martin Hutchings; Luigi Rigacci; Lena Specht; Francesco Merli; Mads Hansen; Caterina Patti; Annika Loft; Francesco Di Raimondo; Francesco D'Amore; Alberto Biggi; Umberto Vitolo; Caterina Stelitano; Rosario Sancetta; Livio Trentin; Stefano Luminari; Emilio Iannitto; Simonetta Viviani; Ivana Pierri; Alessandro Levis
Journal:  J Clin Oncol       Date:  2007-07-23       Impact factor: 44.544

9.  Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

Authors:  Michel Meignan; Andrea Gallamini; Michel Meignan; Andrea Gallamini; Corinne Haioun
Journal:  Leuk Lymphoma       Date:  2009-08

10.  Stromal gene signatures in large-B-cell lymphomas.

Authors:  G Lenz; G Wright; S S Dave; W Xiao; J Powell; H Zhao; W Xu; B Tan; N Goldschmidt; J Iqbal; J Vose; M Bast; K Fu; D D Weisenburger; T C Greiner; J O Armitage; A Kyle; L May; R D Gascoyne; J M Connors; G Troen; H Holte; S Kvaloy; D Dierickx; G Verhoef; J Delabie; E B Smeland; P Jares; A Martinez; A Lopez-Guillermo; E Montserrat; E Campo; R M Braziel; T P Miller; L M Rimsza; J R Cook; B Pohlman; J Sweetenham; R R Tubbs; R I Fisher; E Hartmann; A Rosenwald; G Ott; H-K Muller-Hermelink; D Wrench; T A Lister; E S Jaffe; W H Wilson; W C Chan; L M Staudt
Journal:  N Engl J Med       Date:  2008-11-27       Impact factor: 91.245
View more
  10 in total

1.  Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma.

Authors:  Silvia Fuertes; Xavier Setoain; Armando Lopez-Guillermo; Josep-Lluis Carrasco; Sonia Rodríguez; Jordina Rovira; Francesca Pons
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-23       Impact factor: 9.236

Review 2.  FDG PET/CT in children and adolescents with lymphoma.

Authors:  Regine Kluge; Lars Kurch; Françoise Montravers; Christine Mauz-Körholz
Journal:  Pediatr Radiol       Date:  2013-03-24

3.  An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.

Authors:  Emmanuel Itti; Michel Meignan; Alina Berriolo-Riedinger; Alberto Biggi; Amanda F Cashen; Pierre Véra; Hervé Tilly; Barry A Siegel; Andrea Gallamini; René-Olivier Casasnovas; Corinne Haioun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-07       Impact factor: 9.236

4.  Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma.

Authors:  Wouter J Plattel; Anke van den Berg; Lydia Visser; Anne-Marijn van der Graaf; Jan Pruim; Hans Vos; Bouke Hepkema; Arjan Diepstra; Gustaaf W van Imhoff
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

5.  qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma.

Authors:  Dirk Hasenclever; Lars Kurch; Christine Mauz-Körholz; Andreas Elsner; Thomas Georgi; Hamish Wallace; Judith Landman-Parker; Angelina Moryl-Bujakowska; Michaela Cepelová; Jonas Karlén; Ana Álvarez Fernández-Teijeiro; Andishe Attarbaschi; Alexander Fosså; Jane Pears; Andrea Hraskova; Eva Bergsträsser; Auke Beishuizen; Anne Uyttebroeck; Eckhard Schomerus; Osama Sabri; Dieter Körholz; Regine Kluge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-07       Impact factor: 9.236

6.  Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease.

Authors:  Egesta Lopci; Roberta Burnelli; Luca Guerra; Angelina Cistaro; Arnoldo Piccardo; Pietro Zucchetta; Enrico Derenzini; Alessandra Todesco; Alberto Garaventa; Fabio Schumacher; Piero Farruggia; Salvatore Buffardi; Alessandra Sala; Fiorina Casale; Paolo Indolfi; Samanta Biondi; Andrea Pession; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-11       Impact factor: 9.236

7.  Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.

Authors:  Pierre-Yves Le Roux; Thomas Gastinne; Steven Le Gouill; Emmanuel Nowak; Caroline Bodet-Milin; Solène Querellou; Beatrice Mahe; Viviane Dubruille; Nicolas Blin; Pierre Yves Salaun; Françoise Bodere-Kraeber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-10       Impact factor: 9.236

8.  Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography.

Authors:  Yvette L Kasamon
Journal:  Adv Hematol       Date:  2010-12-22

9.  Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma.

Authors:  Sung-Hoon Jung; Jae-Sook Ahn; Yeo-Kyeoung Kim; Sun-Seog Kweon; Jung-Joon Min; Hee-Seung Bom; Hyeoung-Joon Kim; Yee Soo Chae; Joon Ho Moon; Sang Kyun Sohn; Sang Woo Lee; Byung Hyun Byun; Young Rok Do; Je-Jung Lee; Deok-Hwan Yang
Journal:  BMC Cancer       Date:  2015-03-28       Impact factor: 4.430

10.  Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial.

Authors:  Thomas W Georgi; Lars Kurch; Dirk Hasenclever; Victoria S Warbey; Lucy Pike; John Radford; Osama Sabri; Regine Kluge; Sally F Barrington
Journal:  PLoS One       Date:  2020-04-02       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.